India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GlaxoSmithKline PLC gained the top sales slot in India with Augmentin (amoxicillin/clavulanate) as a result of data analysis firm IMS Health expanding its sales audit coverage in the country
You may also be interested in...
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
Calibrating a medicine price to a lower level to suit local needs is not a new concept for GlaxoSmithKline, which uses a tiered pricing structure, generally calculated based on parameters like GDP, per capita income of a specific country, medical access quotients and health insurance programs.